Lincomycin is a lincosamide antibiotic originally isolated from S. lincolnensis.1,2 It is active against Gram-positive bacteria, including various strains of S. aureus, S. epidermidis, S. pneumoniae, and S. pyogenes (MICs = 0.2-3.2, 0.4-1.8, 0.01-0.8, and 0.04-0.8 ?g/ml, respectively).2 Lincomycin selectively inhibits protein synthesis in purified ribosomes from S. aureus over E. coli (IC50s = 0.03 and 1.7 ?g/ml, respectively, in cell-free assays).3 It is protective against development of mastitis in a mouse model of acute mastitis induced by S. aureus with a 50% protective dose (PD50) value of 3.5 mg/kg.4 Formulations containing lincomycin have been used in the treatment of Gram-positive bacterial infections.
1.Wilson, D.N.The A-Z of bacterial translation inhibitorsCrit. Rev. Biochem. Mol. Biol.44(6)393-433(2009) 2.Spí?ek, J., and ?ezanka, T.Lincomycin, clindamycin and their applicationsAppl. Microbiol. Biotechnol.64(4)455-464(2004) 3.Matzov, D., Eyal, Z., Benhamou, R., et al.Structural insights of lincosamides targeting the ribosome of Staphylococcus aureusNucleic Acids Res.45(17)10284-10292(2017) 4.Yancey, R.J., Jr., Kinney, M.L., and Ford, C.W.Efficacy of lincosaminide antibiotics in the treatment of experimental staphylococcal mastitis in lactating miceJ. Antimicrob. Chemother.15(2)219-232(1985)